Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR

Journal of Experimental and Clinical Cancer Research

Volumn 31, Issue 1, 2012, Pages

  Wang, Fen ^a   Wang, Shuhang ^a   Wang, Zhijie ^a   Duan, Jianchun ^a   An, Tongtong ^a   Zhao, Jun ^a   Bai, Hua ^a   Wang, Jie ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

EGFR mutation; EGFR phosphorylation; Non small cell lung cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; TYROSINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RISK FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84865050504     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-31-65     Document Type: Article

References (43)

1. Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Selvaggi G, Novello S, Torri V, Leonardo E, De Giuli P, Borasio P, Mossetti C, Ardissone F, Lausi P, Scagliotti GV, Ann Oncol 2004 15 28 32 10.1093/annonc/mdh011 14679115
2. Epidermal growth factor receptor family in lung cancer and premalignancy. Franklin WA, Veve R, Hirsch FR, Helfrich BA, Bunn PA, SeminOncol 2002 29 3 14
3. Erlotinib in previously treated non-small-cell lung cancer. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P, Seymour L, N Engl J Med 2005 353 123 32 10.1056/NEJMoa050753 16014882
4. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomized phase III trial. Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, Li LY, Watkins CL, Sellers MV, Lowe ES, Sun Y, Liao ML, Osterlind K, Reck M, Armour AA, Shepherd FA, Lippman SM, Douillard JY, Lancet 2008 372 1809 18 10.1016/S0140-6736(08)61758-4 19027483
5. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. Pérez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabárbara P, Bonomi P, J Clin Oncol 2004 22 3238 47 10.1200/JCO.2004.11.057 15310767
6. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Chou TY, Chiu CH, Li LH, Hsiao CY, Tzen CY, Chang KT, Chen YM, Perng RP, Tsai SF, Tsai CM, Clin Cancer Res 2005 11 3750 7 10.1158/1078-0432.CCR-04-1981 15897572
7. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Taron M, Ichinose Y, Rosell R, Mok T, Massuti B, Zamora L, Mate JL, Manegold C, Ono M, Queralt C, Jahan T, Sanchez JJ, Sanchez-Ronco M, Hsue V, Jablons D, Sanchez JM, Moran T, Clin Cancer Res 2005 11 5878 85 10.1158/1078-0432.CCR-04-2618 16115929
8. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. Hirsch FR, Varella-Garcia M, Bunn PA, Franklin WA, Dziadziuszko R, Thatcher N, Chang A, Parikh P, Pereira JR, Ciuleanu T, von Pawel J, Watkins C, Flannery A, Ellison G, Donald E, Knight L, Parums D, Botwood N, Holloway B, J ClinOncol 2006 24 5034 42 10.1200/JCO.2006.06.3958
9. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M, N Engl J Med 2009 361 947 57 10.1056/NEJMoa0810699 19692680
10. ErbB receptors: directing key signaling networks throughout life. Holbro T, Hynes NE, Annu Rev Pharmacol Toxicol 2004 44 195 217 10.1146/annurev. pharmtox.44.101802.121440 14744244
11. Biological and clinical implications of EGFR mutations in lung cancer. Mitsudomi T, Kosaka T, Yatabe Y, Int J ClinOncol. 2006 11 190 8
12. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. Sequist LV, Bell DW, Lynch TJ, Haber DA, J Clin Oncol 2007 25 587 95 10.1200/JCO.2006.07.3585 17290067
13. The hallmarks of cancer. Hanahan D, Weinberg RA, Cell 2000 100 57 70 10.1016/S0092-8674(00)81683-9 10647931
14. ERBB receptors and cancer: the complexity of targeted inhibitors. Hynes NE, Lane HA, Nat Rev Cancer. 2005 5 341 54 10.1038/nrc1609 15864276
15. Phosphotyrosineinteractome of the ErbB-receptor kinase family. Schulze WX, Deng L, Mann M, MolSystBiol 2005 1 2005.0008
16. Inhibition of EGFR signaling: all mutations are not created equal. Gazdar AF, Minna JD, PLoS Med 2005 2 377 10.1371/journal.pmed.0020377 16288556
17. Common and distinct elements in cellular signaling via EGF and FGF receptors. Schlessinger J, Science 2004 306 1506 7 10.1126/science.1105396 15567848
18. The EGFR family and its ligands in human cancer signaling mechanisms and therapeutic opportunities. Yarden Y, Eur J Cancer 2001 37 3 8 11597398
19. Role of conformational alteration in the epidermal growth factor receptor (EGFR) function. Bishayee S, Biochem Pharmacol 2000 60 1217 23 10.1016/S0006-2952(00)00425-1 11007960
20. Role of network branching in eliciting differential short-term signaling responses in the hypersensitive epidermal growth factor receptor mutants implicated in lung cancer. Purvis J, Ilango V, Radhakrishnan R, Biotechnol Prog 2008 24 540 53 10.1021/bp070405o 18412405
21. The role of individual SH2 domains in mediating association of phospholipase C-gamma1 with the activated EGF receptor. Chattopadhyay A, Vecchi M, Ji Q, Mernaugh R, Carpenter G, J Biol Chem. 1999 274 26091 7 10.1074/jbc.274.37.26091 10473558
22. Requirement of tyr-992 and tyr-1173 in phosphorylation of the epidermal growth factor receptor by ionizing radiation and modulation by SHP2. Sturla LM, Amorino G, Alexander MS, Mikkelsen RB, Valerie K, Schmidt-Ullrichr RK, J BiolChem 2005 280 14597 604
23. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Sordella R, Bell DW, Haber DA, Settleman J, Science 2004 305 1163 7 10.1126/science.1101637 15284455
24. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA, N Engl J Med 2004 350 2129 39 10.1056/NEJMoa040938 15118073
25. Phosphorylation, but not overexpression, of epidermal growth factor receptor is associated with poor prognosis of non-small cell lung cancer patients. Kanematsu T, Yano S, Uehara H, Bando Y, Sone S, Oncol Res 2003 13 289 98 12688680
26. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Moscatello DK, Holgado-Madruga M, Godwin AK, Ramirez G, Gunn G, Zoltick PW, Biegel JA, Hayes RL, Wong AJ, Cancer Res 1995 55 5536 9 7585629
27. Expression of constitutively activated EGFRvIII in non-small cell lung cancer. Okamoto I, Kenyon LC, Emlet DR, Mori T, Sasaki J, Hirosako S, Ichikawa Y, Kishi H, Godwin AK, Yoshioka M, Suga M, Matsumoto M, Wong AJ, Cancer Sci 2003 94 50 6 10.1111/j.1349-7006.2003.tb01351.x 12708474
28. Phosphorylation status of epidermal growth factor receptor is closely associated with responsiveness to gefitinib in pulmonary adenocarcinoma. Hijiya N, Miyawaki M, Kawahara K, Akamine S, Tsuji K, Kadota J, Akizuki S, Uchida T, Matsuura K, Tsukamoto Y, Moriyama M, Hum Pathol 2008 39 316 23 10.1016/j.humpath.2007.10.027 18261621
29. Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study. Emery IF, Battelli C, Auclair PL, Carrier K, Hayes DM, BMC Cancer 2009 9 333 10.1186/1471-2407-9-333 19765296
30. Epidermal growth factor receptor mutations in non-small cell lung cancer influence downstream Akt, MAPK and Stat3 signaling. Zimmer S, Kahl P, Buhl TM, Steiner S, Wardelmann E, Merkelbach-Bruse S, Buettner R, Heukamp LC, J Cancer Res Clin Oncol 2009 135 723 30 10.1007/s00432-008-0509-9 19002495
31. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, Gregorc V, Doglioni C, Sidoni A, Tonato M, Franklin WA, Crino L, Bunn PA, Varella-Garcia M, J Natl Cancer Inst. 2005 97 643 55 10.1093/jnci/dji112 15870435
32. New guidelines to evaluate the response to treatment in solid tumors.European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG, J Natl Cancer Inst 2000 92 205 16 10.1093/jnci/92.3.205 10655437
33. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. Bai H, Mao L, Wang HS, Zhao J, Yang L, An TT, Wang X, Duan CJ, Wu NM, Guo ZQ, Liu YX, Liu HN, Wang YY, Wang J, J Clin Oncol. 2009 27 2653 9 10.1200/JCO.2008.17.3930 19414683
34. Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy. Gazdar AF, Cancer Metastasis Rev. 2010 29 37 48 10.1007/s10555-010-9201-z 20127143
35. Comprehensive analysis of EGFR signaling pathways in Japanese patients with non-small cell lung cancer. Hosokawa S, Toyooka S, Fujiwara Y, Tokumo M, Soh J, Takigawa N, Hotta K, Yoshino T, Date H, Tanimoto M, Kiura K, Lung Cancer. 2009 66 107 13 10.1016/j.lungcan.2009.01.005 19185949
36. Phosphorylated epidermal growth factor receptor and cyclooxygenase-2 expression in localized non-small cell lung cancer. Kim SJ, Rabbani ZN, Dong F, Vollmer RT, Schreiber EG, Dewhirst MW, Vujaskovic Z, Kelley MJ, Med Oncol. 2010 27 91 7 10.1007/s12032-009-9178-z 19235531
37. Immunohistochemical analysis of phosphorylated epidermal growth factor receptor might provide a surrogate marker of EGFR mutation. Endoh H, Ishibashi Y, Yamaki E, Yoshida T, Yajima T, Kimura H, Kosaka T, Onozato R, Tanaka S, Mitsudomi T, Kuwano H, Lung Cancer. 2009 63 241 6 10.1016/j.lungcan.2008.05.013 18585821
38. Mutant epidermal growth factor receptors as targets for cancer therapy. Lorimer IA, Curr Cancer Drug Targets. 2002 2 91 102 10.2174/1568009023333926 12188912
39. Serine mutations that abrogate ligand-induced ubiquitination and internalization of the EGF receptor do not affect c-Cbl association with the receptor. Oksvold MP, Thien CB, Widerberg J, Chantry A, Huitfeldt HS, Langdon WY, Oncogene. 2003 22 8509 18 10.1038/sj.onc.1207117 14627991
40. Epidermal growth factor receptor: mechanisms of activation and signaling. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW, Exp Cell Res. 2003 284 31 53 10.1016/S0014-4827(02)00098-8 12648464
41. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. Helfrich BA, Raben D, Varella-Garcia M, Gustafson D, Chan DC, Bemis L, Coldren C, Barón A, Zeng C, Franklin WA, Hirsch FR, Gazdar A, Minna J, Bunn PA, Clin Cancer Res. 2006 12 7117 25 10.1158/1078-0432.CCR-06- 0760 17145836
42. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Amann J, Kalyankrishna S, Massion PP, Ohm JE, Girard L, Shigematsu H, Peyton M, Juroske D, Huang Y, Stuart Salmon J, Kim YH, Pollack JR, Yanagisawa K, Gazdar A, Minna JD, Kurie JM, Carbone DP, Cancer Res 2005 65 226 35 15665299
43. Phosphorylation status of epidermal growth factor receptor is closely associated with responsiveness to gefitinib in pulmonary adenocarcinoma. Hijiya N, Miyawaki M, Kawahara K, Akamine S, Tsuji K, Kadota J, Akizuki S, Uchida T, Matsuura K, Tsukamoto Y, Moriyama M, Hum Pathol. 2008 39 316 23 10.1016/j.humpath.2007.10.027 18261621